8158 — China Regenerative Medicine International Cashflow Statement
0.000.00%
Last trade - 00:00- HK$139.96m
- HK$208.72m
- HK$90.62m
- 20
- 39
- 43
- 21
Annual cashflow statement for China Regenerative Medicine International, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -142 | 64.3 | 8.27 | -108 | 17.8 |
| Depreciation | |||||
| Non-Cash Items | -137 | -41.2 | 8.06 | 84 | -11.5 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -122 | -26.2 | -34.1 | 23.2 | 1.06 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -399 | -3.02 | -17.7 | 10.8 | 18.3 |
| Capital Expenditures | 0 | -0.809 | -2.59 | -0.274 | -0.627 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 327 | 10.1 | 0.001 | 0.012 | 0.005 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 327 | 9.27 | -2.59 | -0.262 | -0.622 |
| Financing Cash Flow Items | 29.7 | -0.174 | 0 | -0.979 | -0.485 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 67.4 | -1.39 | 7.32 | -8.34 | 2.37 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.52 | 5.16 | -8.08 | 1.49 | 19.4 |